You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ublituximab

Showing 1 - 25 of 32
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Ublituximab
  • Fort Collins, Colorado
  • +1 more
May 26, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Jan 20, 2023

Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Fort Myers, Saint Petersburg, Nashville (Ublituximab, Umbralisib)

Terminated
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Fort Myers, Florida
  • +2 more
Jul 20, 2022

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
Aug 19, 2022

Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • No intervention
  • (no location specified)
Nov 16, 2023

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jul 31, 2022

Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ublituximab
  • +4 more
  • Boston, Massachusetts
  • +2 more
Aug 19, 2022

Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL Trial in New York (Umbralisib, Ublituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • New York, New York
    Weill Cornell Medicine
Mar 29, 2022

Marginal Zone Lymphoma, Follicular Lymphoma Trial in Aurora (Ublituximab, Umbralisib)

Suspended
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Aurora, Colorado
    University of Colorado Hospital
Feb 22, 2022

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,

Terminated
  • Non-Hodgkins Lymphoma
  • +6 more
  • Huntsville, Alabama
  • +1 more
May 5, 2022

Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in United States (TGR-1202, TGR-1202 + Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +16 more
Jul 20, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (Ublituximab, Ibrutinib)

Completed
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Huntsville, Alabama
  • +17 more
Oct 21, 2022

Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ublituximab
  • Pasadena, California
  • +7 more
Aug 19, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Ublituximab, Umbralisib, Venetoclax)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +49 more
Jan 20, 2023

Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)

Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 8, 2021

B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)

Active, not recruiting
  • B-Cell Lymphoma
  • Heidelberg, Victoria, Australia
  • +2 more
Jan 20, 2023

B-cell Non Hodgkin Lymphoma, Richter's Transformation Trial in United States (Cosibelimab, Cosibelimab + Ublituximab +

Terminated
  • B-cell Non Hodgkin Lymphoma
  • Richter's Transformation
  • Cosibelimab
  • Cosibelimab + Ublituximab + Bendamustine combination
  • Huntsville, Alabama
  • +8 more
Aug 19, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Phoenix, Arizona
  • +12 more
Nov 11, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Carlsbad, California
  • +13 more
Nov 5, 2021

Multiple Sclerosis Trial in United States (Ublituximab, Placebo)

Completed
Has Results
  • Multiple Sclerosis
  • Ublituximab
  • Placebo
  • Phoenix, Arizona
  • +11 more
Jun 22, 2021

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Relapsing Multiple Sclerosis (RMS) Trial in Worldwide (Ublituximab)

Enrolling by invitation
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • Pasadena, California
  • +84 more
Mar 22, 2022